Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 handwiki Sirius Huang -- 6654 2022-11-09 01:37:43

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
HandWiki. COVID-19 Vaccine. Encyclopedia. Available online: https://encyclopedia.pub/entry/33656 (accessed on 23 September 2026).
HandWiki. COVID-19 Vaccine. Encyclopedia. Available at: https://encyclopedia.pub/entry/33656. Accessed September 23, 2026.
HandWiki. "COVID-19 Vaccine" Encyclopedia, https://encyclopedia.pub/entry/33656 (accessed September 23, 2026).
HandWiki. (2022, November 09). COVID-19 Vaccine. In Encyclopedia. https://encyclopedia.pub/entry/33656
HandWiki. "COVID-19 Vaccine." Encyclopedia. Web. 09 November, 2022.
COVID-19 Vaccine
Edit
The content is sourced from: https://handwiki.org/wiki/Medicine:COVID-19_vaccine

A COVID‑19 vaccine is a hypothetical vaccine in development against coronavirus disease 2019 (COVID‑19). Although no candidate has completed clinical trials to prove its safety and efficacy, there are multiple efforts in progress to develop one. As of July 2020, there are 24 vaccine candidates planned or undergoing clinical trials, with two beginning Phase III and seven in Phase I-II. Previous attempts to develop a vaccine against the coronavirus diseases SARS and MERS established considerable knowledge about the structure and function of coronaviruses – which accelerated rapid development during early 2020 of varied technology platforms for a COVID‑19 vaccine – but all the previous coronavirus vaccine candidates failed in early-stage clinical trials, with none being advanced to licensing. The Coalition for Epidemic Preparedness Innovations (CEPI) – which is organizing a US$2 billion worldwide fund for rapid investment and development of vaccine candidates – indicated in April that a vaccine may be available under emergency use protocols in less than 12 months or by early 2021. On 4 May 2020, the WHO organized a telethon which received US$8.1 billion in pledges from forty countries to support rapid development of vaccines to prevent COVID‑19 infections. At the same time, the WHO also announced deployment of an international "Solidarity trial" for simultaneous evaluation of several vaccine candidates reaching Phase II-III clinical trials.

clinical trials coronavirus disease 2019 coronavirus vaccine

References

  1. Grenfell, Rob; Drew, Trevor (17 February 2020). "Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus". https://www.sciencealert.com/who-says-a-coronavirus-vaccine-is-18-months-away. 
  2. "COVID-19 vaccine development pipeline (Refresh URL to update)". Vaccine Centre, London School of Hygiene and Tropical Medicine. 2020-07-15. https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/. 
  3. "COVID-19 vaccine tracker (Choose vaccines tab, apply filters to view select data)". Milken Institute. 2020-06-23. https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viwDBH7b6FjmIBX5x?blocks=hide. 
  4. "Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus". Avian Pathology 32 (6): 567–82. December 2003. doi:10.1080/03079450310001621198. PMID 14676007.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7154303
  5. "Effects of a SARS-associated coronavirus vaccine in monkeys". Lancet 362 (9399): 1895–6. December 2003. doi:10.1016/S0140-6736(03)14962-8. PMID 14667748.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7112457
  6. "Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice". Vaccine 32 (45): 5975–82. October 2014. doi:10.1016/j.vaccine.2014.08.058. PMID 25192975.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7115510
  7. "Development of SARS vaccines and therapeutics is still needed". Future Virology 8 (1): 1–2. January 2013. doi:10.2217/fvl.12.126. PMID 32201503.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7079997
  8. "SARS (severe acute respiratory syndrome)". National Health Service. 5 March 2020. https://www.nhs.uk/conditions/sars/. 
  9. Shehata, Mahmoud M.; Gomaa, Mokhtar R.; Ali, Mohamed A.; Kayali, Ghazi (20 January 2016). "Middle East respiratory syndrome coronavirus: a comprehensive review". Frontiers of Medicine 10 (2): 120–136. doi:10.1007/s11684-016-0430-6. PMID 26791756.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7089261
  10. "SARS veterans tackle coronavirus". Nature 490 (7418): 20. October 2012. doi:10.1038/490020a. PMID 23038444. Bibcode: 2012Natur.490...20B.  https://dx.doi.org/10.1038%2F490020a
  11. "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial". The Lancet. Infectious Diseases 19 (9): 1013–1022. September 2019. doi:10.1016/S1473-3099(19)30266-X. PMID 31351922.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7185789
  12. "Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus". Frontiers in Microbiology 10: 1781. 2019. doi:10.3389/fmicb.2019.01781. PMID 31428074.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=6688523
  13. "World Health Organization timeline – COVID-19". World Health Organization. 2020-04-27. https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19. 
  14. Thanh Le, Tung; Andreadakis, Zacharias; Kumar, Arun; Gómez Román, Raúl; Tollefsen, Stig; Saville, Melanie; Mayhew, Stephen (9 April 2020). "The COVID-19 vaccine development landscape". Nature Reviews Drug Discovery 19 (5): 305–306. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591. https://www.nature.com/articles/d41573-020-00073-5. Retrieved 11 April 2020. 
  15. "Responding to Covid-19: A once-in-a-century pandemic?". The New England Journal of Medicine 382 (18): 1677–1679. February 2020. doi:10.1056/nejmp2003762. PMID 32109012.  https://dx.doi.org/10.1056%2Fnejmp2003762
  16. "Covid-19: Navigating the uncharted". The New England Journal of Medicine 382 (13): 1268–1269. March 2020. doi:10.1056/nejme2002387. PMID 32109011.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7121221
  17. "Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine". World Health Organization. 2020-04-27. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine. "It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale." 
  18. Gavin Yamey, Marco Schäferhoff, Richard Hatchett, Muhammad Pate, Feng Zhao, Kaci Kennedy McDade (2020-05-02). "Ensuring global access to COVID‑19 vaccines". The Lancet 305: 1405–6. https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)30763-7.pdf. "CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion. This estimate includes phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.". 
  19. Gates, Bill (2020-04-30). "The vaccine race explained: What you need to know about the COVID-19 vaccine". The Gates Notes. https://www.gatesnotes.com/Health/What-you-need-to-know-about-the-COVID-19-vaccine. 
  20. Sanger, David E.; Kirkpatrick, David D.; Zimmer, Carl; Thomas, Katie; Wee, Sui-Lee (2020-05-02). "With Pressure Growing, Global Race for a Vaccine Intensifies". The New York Times. ISSN 0362-4331. https://www.nytimes.com/2020/05/02/us/politics/vaccines-coronavirus-research.html. 
  21. "Commitment and call to action: Global collaboration to accelerate new COVID-19 health technologies". World Health Organization. 2020-04-24. https://www.who.int/news-room/detail/24-04-2020-commitment-and-call-to-action-global-collaboration-to-accelerate-new-covid-19-health-technologies. 
  22. "Landmark global collaboration launched to defeat COVID-19 pandemic". CEPI. 2020-04-24. https://cepi.net/news_cepi/landmark-global-collaboration-launched-to-defeat-covid-19-pandemic/. "The global nature of a pandemic means that any vaccine or medicine that is successfully developed will be needed immediately all over the world. That means that the challenge we face is not only one of R&D but one of manufacturing at scale, and equitable access." 
  23. Damon Wake (2020-05-04). "World leaders urge cooperation in vaccine hunt, raise $8 billion". Yahoo Finance. https://finance.yahoo.com/news/eu-hosts-virus-telethon-seeking-first-7-5-003500556.html. 
  24. Julie Steenhuysen; Peter Eisler; Allison Martell; Stephanie Nebehay (2020-04-27). "Special Report: Countries, companies risk billions in race for coronavirus vaccine". Reuters. https://www.reuters.com/article/health-coronavirus-vaccine-idUSL2N2CF0JG. 
  25. Hamilton, Isobel Asher (2020-05-01). "Bill Gates thinks there are 8 to 10 promising coronavirus vaccine candidates and one could be ready in as little as 9 months". Business Insider. https://www.businessinsider.com/bill-gates-10-promising-coronavirus-vaccine-candidates-2020-5. 
  26. "GloPID: Novel coronavirus COVID-19". https://www.glopid-r.org/our-work/novel-coronavirus-covid-19. 
  27. "Government of Canada's research response to COVID-19". Government of Canada. 2020-04-23. https://www.canada.ca/en/public-health/services/publications/diseases-conditions/covid-19-government-canada-research-response.html. 
  28. "ISARIC: COVID-19 clinical research resources". ISARIC. 2020-04-27. https://isaric.tghn.org/covid-19-clinical-research-resources/. 
  29. "Global Vaccine Summit 2020: World leaders make historic commitments to provide equal access to vaccines for all". Global Alliance for Vaccines and Immunisation. 2020-06-04. https://www.gavi.org/news/media-room/world-leaders-make-historic-commitments-provide-equal-access-vaccines-all. 
  30. "COVID-19: Gavi steps up response to pandemic". Global Alliance for Vaccines and Immunisation. 2020-04-27. https://www.gavi.org/news/media-room/covid-19-gavi-steps-response-pandemic. 
  31. "Bill & Melinda Gates Foundation pledges US$1.6 billion to Gavi, the Vaccine Alliance, to protect the next generation with lifesaving vaccines". PR Newswire (The Bill & Melinda Gates Foundation). 2020-06-04. https://www.prnewswire.com/news-releases/bill--melinda-gates-foundation-pledges-1-6-billion-to-gavi-the-vaccine-alliance-to-protect-the-next-generation-with-lifesaving-vaccines-301070878.html. 
  32. Abedi, Maham (23 March 2020). "Canada to spend $192M on developing COVID-19 vaccine". Global News. https://globalnews.ca/news/6717883/coronavirus-canada-vaccine-spending/. 
  33. "Government of Canada funds 49 additional COVID-19 research projects – Details of the funded projects". Government of Canada. 23 March 2020. https://www.canada.ca/en/institutes-health-research/news/2020/03/government-of-canada-funds-49-additional-covid-19-research-projects-details-of-the-funded-projects.html. 
  34. Aiello, Rachel (2020-05-04). "'A global challenge': PM Trudeau commits $850 million to global fight against COVID-19". CTV News. https://www.ctvnews.ca/health/coronavirus/a-global-challenge-pm-trudeau-commits-850-million-to-global-fight-against-covid-19-1.4923565. 
  35. Takada, Noriyuki; Satake, Minoru (2020-05-02). "US and China unleash wallets in race for coronavirus vaccine". Nikkei Asian Review. https://asia.nikkei.com/Spotlight/Coronavirus/US-and-China-unleash-wallets-in-race-for-coronavirus-vaccine. 
  36. Yuliya Talmazan, Keir Simmons, Laura Saravia (2020-05-18). "China's Xi announces $2B for coronavirus response as WHO faces calls for investigation". NBC News. https://www.nbcnews.com/news/world/coronavirus-who-faces-global-call-investigation-general-assembly-n1209061. 
  37. "CEPI: Our vaccine and platform portfolio". Coalition for Epidemic Preparedness Innovation (CEPI). 2020-04-30. https://cepi.net/research_dev/our-portfolio/. 
  38. "CEPI collaborates with the Institut Pasteur in a consortium to develop COVID-19 vaccine". Coalition for Epidemic Preparedness Innovations. 19 March 2020. https://cepi.net/news_cepi/cepi-collaborates-with-the-institut-pasteur-in-a-consortium-to-develop-covid-19-vaccine/. 
  39. "Coronavirus: Commission offers financing to innovative vaccines company CureVac". European Commission. 16 March 2020. https://ec.europa.eu/commission/presscorner/detail/en/ip_20_474. 
  40. "Corona-Impfstoff: Bundesregierung beteiligt sich an Impfstoffhersteller CureVac" (in de). Der Spiegel. https://www.spiegel.de/wirtschaft/bundesregierung-beteiligt-sich-an-impfstoffhersteller-curevac-a-2c915a65-5e89-407c-91d0-8fa2200efa00. 
  41. Morriss, Emma (2020-04-22). "Government launches coronavirus vaccine taskforce as human clinical trials start". Pharmafield. https://pharmafield.co.uk/pharma_news/government-launches-coronavirus-vaccine-taskforce-as-human-clinical-trials-start/. 
  42. Gartner, Annelies; Roberts, Lizzie (2020-05-03). "How close are we to a coronavirus vaccine? Latest news on UK trials". The Telegraph. ISSN 0307-1235. https://www.telegraph.co.uk/global-health/science-and-disease/coronavirus-vaccine-uk-trials-news-latest-update-covid-19/. 
  43. "Landmark partnership announced for development of COVID-19 vaccine". University of Oxford. 2020-04-30. http://www.ox.ac.uk/news/2020-04-30-landmark-partnership-announced-development-covid-19-vaccine. 
  44. Kuznia, Robert; Polglase, Katie; Mezzofiore, Gianluca (2020-05-01). "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN. https://www.cnn.com/2020/05/01/us/coronavirus-moderna-vaccine-invs/index.html. 
  45. Lee, Carol E; Welker, Kristen; Perlmutter-Gumbiner, Elyse (2020-05-01). "Health officials eyeing at least one of 14 potential coronavirus vaccines to fast-track". NBC News. https://www.nbcnews.com/politics/white-house/health-officials-eyeing-least-one-14-potential-coronavirus-vaccines-fast-n1198326. 
  46. Cohen, Jon (2020-05-15). "U.S. 'Warp Speed' vaccine effort comes out of the shadows". Science 368 (6492): 692–693. doi:10.1126/science.368.6492.692. ISSN 0036-8075. PMID 32409451. https://science.sciencemag.org/content/368/6492/692. Retrieved 15 May 2020. 
  47. Justin Sink, Jordan Fabian, Riley Griffin (2020-05-15). "Trump introduces 'Warp Speed' leaders to hasten COVID-19 vaccine". Bloomberg. https://www.bloomberg.com/news/articles/2020-05-15/trump-to-introduce-warp-speed-leaders-after-vaccine-criticism. 
  48. Riley Griffith, Jennifer Jacobs (2020-06-03). "White House Works With Seven Drugmakers in 'Warp Speed' Push". Bloomberg. https://www.bloomberg.com/news/articles/2020-06-03/white-house-working-with-seven-drugmakers-in-warp-speed-push. 
  49. "Draft landscape of COVID 19 candidate vaccines". World Health Organization. 2020-07-21. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines. 
  50. "An international randomised trial of candidate vaccines against COVID-19: Outline of Solidarity vaccine trial". World Health Organization. 2020-04-09. https://www.who.int/blueprint/priority-diseases/key-action/Outline_CoreProtocol_vaccine_trial_09042020.pdf. 
  51. "Adaptive designs in clinical trials: why use them, and how to run and report them". BMC Medicine 16 (1): 29. February 2018. doi:10.1186/s12916-018-1017-7. PMID 29490655.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5830330
  52. "Adaptive designs for clinical trials of drugs and biologics: Guidance for industry". U.S. Food and Drug Administration (FDA). 1 November 2019. https://www.fda.gov/media/78495/download. 
  53. McGrail, Samantha (2020-04-15). "Sanofi, GSK partner to develop adjuvanted COVID-19 vaccine". PharmaNewsIntelligence. https://pharmanewsintel.com/news/sanofi-gsk-partner-to-develop-adjuvanted-covid-19-vaccine. 
  54. "R&D Blueprint: A coordinated global research roadmap – 2019 novel coronavirus". World Health Organization. 2020-03-01. https://www.who.int/blueprint/priority-diseases/key-action/Coronavirus_Roadmap_V9.pdf?ua=1. 
  55. Jeong-ho, Lee; Zheng, William; Zhou, Laura (26 January 2020). "Chinese scientists race to develop vaccine as coronavirus death toll jumps". South China Morning Post. https://www.scmp.com/news/china/society/article/3047676/number-coronavirus-cases-china-doubles-spread-rate-accelerates. 
  56. Wee, Sui-Lee (2020-05-04). "China's coronavirus vaccine drive empowers a troubled industry". The New York Times. ISSN 0362-4331. https://www.nytimes.com/2020/05/04/business/coronavirus-china-vaccine.html. 
  57. Simpson, Shmona; Kaufmann, Michael C.; Glozman, Vitaly; Chakrabarti, Ajoy (May 2020). "Disease X: accelerating the development of medical countermeasures for the next pandemic". The Lancet. Infectious Diseases 20 (5): e108–e115. doi:10.1016/S1473-3099(20)30123-7. ISSN 1474-4457. PMID 32197097.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7158580
  58. "Clinical Development Success Rates 2006-2015". BIO Industry Analysis. June 2016. https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf. 
  59. Tom Blackwell (2020-04-20). "COVID-19 vaccine researchers say pandemic lockdown placing many serious obstacles to their work". National Post. https://nationalpost.com/news/covid-19-vaccine-researchers-say-pandemic-lockdown-placing-many-serious-obstacles-to-their-work. 
  60. Justin Chen (2020-05-04). "Covid-19 has shuttered labs. It could put a generation of researchers at risk". STAT. https://www.statnews.com/2020/05/04/coronavirus-lab-shutdowns-impact-on-scientists-research-delays/. 
  61. "Vaccine Safety – Vaccines". US Department of Health and Human Services. https://www.vaccines.gov/basics/safety. 
  62. "The drug development process". U.S. Food and Drug Administration (FDA). 4 January 2018. https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process. 
  63. "Investigating a Vaccine Against COVID-19". https://clinicaltrials.gov/ct2/show/NCT04400838. 
  64. Zhu, Feng-Cai; Guan, Xu-Hua; Li, Yu-Hua; Huang, Jian-Ying; Jiang, Tao; Hou, Li-Hua et al. (July 2020). "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial" (PDF). Lancet. doi:10.1016/s0140-6736(20)31605-6. ISSN 0140-6736. https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931605-6. 
  65. "A Phase II Clinical Trial to Evaluate the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector)". https://clinicaltrials.gov/ct2/show/NCT04341389. 
  66. "The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19". National Research Council, Government of Canada. 2020-05-12. https://www.canada.ca/en/national-research-council/news/2020/05/the-national-research-council-of-canada-and-cansino-biologics-inc-announce-collaboration-to-advance-vaccine-against-covid-19.html. 
  67. "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report" (PDF). New England Journal of Medicine. July 2020. doi:10.1056/NEJMoa2022483. PMID 32663912. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022483. 
  68. "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report Supplementary appendix". New England Journal of Medicine. July 2020. doi:10.1056/NEJMoa2022483. PMID 32663912. https://www.nejm.org/doi/suppl/10.1056/NEJMoa2022483/suppl_file/nejmoa2022483_appendix.pdf. 
  69. "Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)". 25 February 2020. https://clinicaltrials.gov/ct2/show/NCT04283461. 
  70. "EudraCT Number 2020-001038-36". European Union. https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE. 
  71. "Mainzer Unternehmen Biontech testet Corona-Impfstoff" (in de). swr.online. SWR. 22 April 2020. https://www.swr.de/swraktuell/rheinland-pfalz/mainz/biontech-impfstoff-coronavirus-100.html. 
  72. "Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults". https://clinicaltrials.gov/ct2/show/NCT04368728. 
  73. Sahin, Ugur; Muik, Alexander; Derhovanessian, Evelyna; Vogler, Isabel; Kranz, Lena M; Vormehr, Mathias et al.. "Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine". medRxiv. doi:10.1101/2020.07.17.20140533v1. https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1.full.pdf. 
  74. "Safety and Immunogenicity Study of 2019-nCoV Vaccine (Inactivated) for Prophylaxis SARS CoV-2 Infection (COVID-19) (Xuzhou)". https://clinicaltrials.gov/ct2/show/NCT04352608. 
  75. "Safety and Immunogenicity Study of 2019-nCoV Vaccine (Inactivated) for Prophylaxis SARS CoV-2 Infection (COVID-19) (Renqui)". https://clinicaltrials.gov/ct2/show/NCT04383574. 
  76. "IVI, INOVIO, and KNIH to partner with CEPI in a Phase I/II clinical trial of INOVIO's COVID-19 DNA vaccine in South Korea". International Vaccine Institute. 2020-04-16. https://www.ivi.int/ivi-inovio-and-knih-to-partner-with-cepi-in-a-phase-i-ii-clinical-trial-of-inovios-covid-19-dna-vaccine-in-south-korea/. 
  77. "Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers". https://clinicaltrials.gov/ct2/show/NCT04336410. 
  78. "Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19". https://clinicaltrials.gov/ct2/show/NCT04412538. 
  79. "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". https://clinicaltrials.gov/ct2/show/NCT04463472. 
  80. "Safety and Immunity of Covid-19 aAPC Vaccine". https://clinicaltrials.gov/ct2/show/NCT04299724. 
  81. "Immunity and Safety of Covid-19 Synthetic Minigene Vaccine". https://clinicaltrials.gov/ct2/show/NCT04276896. 
  82. "A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated novel coronavirus pneumonia vaccine (vero cells)". Chinese Clinical Trial Registry. 2020-04-11. http://www.chictr.org.cn/showprojen.aspx?proj=52227. 
  83. "Draft landscape of COVID-19 candidate vaccines – 2 June 2020". World Health Organization. 2020-06-02. https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines. 
  84. "ISRCTN17072692: Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women" (in en). https://www.isrctn.com/ISRCTN17072692. 
  85. "Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant". https://clinicaltrials.gov/ct2/show/NCT04368988. 
  86. "An Open Study of the Safety, Tolerability and Immunogenicity of "Gam-COVID-Vac Lyo@ Vaccine". https://clinicaltrials.gov/ct2/show/NCT04437875. 
  87. "Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". https://clinicaltrials.gov/ct2/show/NCT04445389. 
  88. "S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 2020-06-19. https://www.reuters.com/article/health-coronavirus-genexine-vaccine-idUSL4N2DW1T3. 
  89. "SCB-2019 as COVID-19 Vaccine". https://clinicaltrials.gov/ct2/show/NCT04405908. 
  90. "Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial". Clinical Trials Arena. 2020-06-20. https://www.clinicaltrialsarena.com/news/clover-vaccine-covid-19-trial/. 
  91. "Monovalent Recombinant COVID19 Vaccine". https://clinicaltrials.gov/ct2/show/NCT04453852. 
  92. "A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults". https://clinicaltrials.gov/ct2/show/NCT04449276. 
  93. "Chinese Clinical Trial Register (ChiCTR) - The world health organization international clinical trials registered organization registered platform". http://www.chictr.org.cn/showprojen.aspx?proj=55524. 
  94. "Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine". https://clinicaltrials.gov/ct2/show/NCT04445194. 
  95. "Safety, Tolerability and Immunogenicity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years". https://clinicaltrials.gov/ct2/show/NCT04450004. 
  96. St. Philip, Elizabeth; Favaro, Avis; MacLeod, Meredith (2020-07-14). "The hunt for a vaccine: Canadian company begins human testing of COVID-19 candidate". CTV News. https://www.ctvnews.ca/health/coronavirus/the-hunt-for-a-vaccine-canadian-company-begins-human-testing-of-covid-19-candidate-1.5022960. 
  97. Vishwadha Chander (2020-07-14). "Canada's Medicago begins human trials of plant-based COVID-19 vaccine". National Post (Reuters). https://nationalpost.com/news/canada/canadas-medicago-begins-human-trials-of-plant-based-covid-19-vaccine. 
  98. "COVID-19 vaccine and therapeutics tracker". BioRender. 2020-06-21. https://biorender.com/covid-vaccine-tracker. 
  99. Zimmer, Carl (2020-05-20). "Prototype Vaccine Protects Monkeys From Coronavirus" (in en-US). The New York Times. ISSN 0362-4331. https://www.nytimes.com/2020/05/20/health/coronavirus-vaccine-harvard.html. 
  100. "Public statement for collaboration on COVID-19 vaccine development". World Health Organization. 2020-04-13. https://www.who.int/news-room/detail/13-04-2020-public-statement-for-collaboration-on-covid-19-vaccine-development. 
  101. "Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study". Lancet Global Health 6 (12): e1386–96. December 2018. doi:10.1016/S2214-109X(18)30346-2. PMID 30342925.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7164811
  102. "Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies". Assay Guidance Manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences. 1 July 2016. https://www.ncbi.nlm.nih.gov/books/NBK92015/. 
  103. "Innovation in the pharmaceutical industry: New estimates of R&D costs". Journal of Health Economics 47: 20–33. May 2016. doi:10.1016/j.jhealeco.2016.01.012. PMID 26928437. https://dukespace.lib.duke.edu/dspace/bitstream/handle/10161/12742/DiMasi-Grabowski-Hansen-RnD-JHE-2016.pdf;sequence=1. Retrieved 21 April 2020. 
  104. Kleinnijenhuis, J; van Crevel, R; Netea, MG (January 2015). "Trained immunity: consequences for the heterologous effects of BCG vaccination.". Transactions of the Royal Society of Tropical Medicine and Hygiene 109 (1): 29–35. doi:10.1093/trstmh/tru168. PMID 25573107.  https://dx.doi.org/10.1093%2Ftrstmh%2Ftru168
  105. de Vrieze, Jop (23 March 2020). "Can a century-old TB vaccine steel the immune system against the new coronavirus?". Science. doi:10.1126/science.abb8297.  https://dx.doi.org/10.1126%2Fscience.abb8297
  106. "BCG-induced trained immunity: can it offer protection against COVID-19?". Nat. Rev. Immunol. 20 (6): 335–337. June 2020. doi:10.1038/s41577-020-0337-y. PMID 32393823.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7212510
  107. "BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)". Proc. Natl. Acad. Sci. U.S.A.. July 2020. doi:10.1073/pnas.2008410117. PMID 32647056.  https://dx.doi.org/10.1073%2Fpnas.2008410117
  108. "BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy". J Immunother Cancer 8 (2). July 2020. doi:10.1136/jitc-2020-001119. PMID 32636240.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7342862
  109. "Bacille Calmette-Guérin (BCG) vaccination and COVID-19". 12 April 2020. https://www.who.int/news-room/commentaries/detail/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19. 
  110. "EudraCT 2020-000919-69". https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000919-69/NL. 
  111. "Murdoch Children's Research Institute to trial preventative vaccine for COVID-19 healthcare workers". https://www.mcri.edu.au/news/murdoch-children%E2%80%99s-research-institute-trial-preventative-vaccine-covid-19-healthcare-workers. 
  112. "BCG Vaccination to Protect Healthcare Workers Against COVID-19". US National Library of Medicine, National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT04327206. 
  113. "BCG Vaccine for Health Care Workers as Defense Against SARS-COV2". US National Library of Medicine, National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT04348370. 
  114. "Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19". US National Library of Medicine, National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT04350931. 
  115. "EudraCT Number 2020-001591-15". https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001591-15/NL. 
  116. "Performance Evaluation of BCG vs COVID-19". US National Library of Medicine, National Institutes of Health. 24 April 2020. https://clinicaltrials.gov/ct2/show/NCT04362124. 
  117. "COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement". US National Library of Medicine, National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT04369794. 
  118. "EudraCT Number 2020-001678-31". EU. https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001678-31/FR. 
  119. "Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic". US National Library of Medicine, National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT04373291. 
  120. "BCG Vaccination for Healthcare Workers in COVID-19 Pandemic – Full Text View – ClinicalTrials.gov". US National Library of Medicine, National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT04379336. 
  121. "Bacillus Calmette-guérin Vaccination to Prevent COVID-19". U.S. National Library of Medicine, National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT04414267. 
  122. "Measles Vaccine in HCW". US National Library of Medicine, National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT04357028. 
  123. Diamond, Michael S; Pierson, Theodore C (2020-05-13). "The challenges of vaccine development against a new virus during a pandemic". Cell Host and Microbe. doi:10.1016/j.chom.2020.04.021. PMID 32407708.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7219397
  124. Thorp, H. Holden (27 March 2020). "Underpromise, overdeliver". Science 367 (6485): 1405. doi:10.1126/science.abb8492. PMID 32205459.  https://dx.doi.org/10.1126%2Fscience.abb8492
  125. "Ten health issues WHO will tackle this year". World Health Organization. 2019. https://www.who.int/emergencies/ten-threats-to-global-health-in-2019. 
  126. Dubé, Eve; Laberge, Caroline; Guay, Maryse; Bramadat, Paul; Roy, Réal; Bettinger, Julie (2013-08-01). "Vaccine hesitancy: an overview". Human Vaccines and Immunotherapeutics 9 (8): 1763–1773. doi:10.4161/hv.24657. ISSN 2164-554X. PMID 23584253.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3906279
  127. Iwasaki, Akiko; Yang, Yexin (2020-04-21). "The potential danger of suboptimal antibody responses in COVID-19". Nature Reviews Immunology. doi:10.1038/s41577-020-0321-6. ISSN 1474-1733. PMID 32317716.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7187142
  128. Wiedermann, Ursula; Garner-Spitzer, Erika; Wagner, Angelika (2016). "Primary vaccine failure to routine vaccines: Why and what to do?". Human Vaccines and Immunotherapeutics 12 (1): 239–243. doi:10.1080/21645515.2015.1093263. ISSN 2164-554X. PMID 26836329.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4962729
  129. Cohen, Jon (2020-06-19). "Pandemic vaccines are about to face the real test". Science 368 (6497): 1295-6. doi:10.1126/science.368.6497.1295. https://science.sciencemag.org/content/368/6497/1295. Retrieved 20 June 2020. 
  130. Hu, Yuwei; Leng, Shumei (2020-06-16). "Brazil joins China in quest for vaccine". Global Times-China. https://www.globaltimes.cn/content/1191829.shtml. 
  131. Jacqueline Howard; Veronica Stracqualursi (2020-06-18). "Fauci warns of 'anti-science bias' being a problem in US". CNN. https://www.cnn.com/2020/06/18/politics/anthony-fauci-coronavirus-anti-science-bias/index.html. 
  132. "How flu vaccine effectiveness and efficacy are measured". Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, US Department of Health and Human Services. 2016-01-29. https://www.cdc.gov/flu/vaccines-work/effectivenessqa.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fprofessionals%2Fvaccination%2Feffectivenessqa.htm. 
  133. "Principles of epidemiology, Section 8: Concepts of disease occurrence". Centers for Disease Control and Prevention, Center for Surveillance, Epidemiology, and Laboratory Services, US Department of Health and Human Services. 2012-05-18. https://www.cdc.gov/csels/dsepd/ss1978/lesson1/section8.html. 
  134. Alimuddin Zumla; David S Hui; Stanley Perlman (2015-09-11). "Middle East respiratory syndrome". Lancet 386: 995–1007. doi:10.1016/S0140-6736(15)60454-8. PMID 26049252.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=4721578
  135. "Is the coronavirus mutating? Yes. But here’s why you don’t need to panic". Science News. 26 May 2020. https://www.sciencenews.org/article/coronavirus-covid19-mutations-strains-variants. 
  136. Gates, Bill (2020-04-23). "The first modern pandemic: The scientific advances we need to stop COVID-19". The Gates Notes. https://www.gatesnotes.com/Health/Pandemic-Innovation. 
  137. Stevis-Gridneff, Matina; Jakes, Lara (2020-05-04). "World Leaders Join to Pledge $8 Billion for Vaccine as U.S. Goes It Alone" (in en-US). The New York Times. ISSN 0362-4331. https://www.nytimes.com/2020/05/04/world/europe/eu-coronavirus-vaccine.html. 
  138. Blanchfield, Mike (2020-04-30). "Global philanthropists, experts call for COVID-19 vaccine distribution plan". The Toronto Star. https://www.thestar.com/news/canada/2020/04/30/global-philanthropists-experts-call-for-covid-19-vaccine-distribution-plan.html. 
  139. Eyal, Nir; Lipsitch, Marc; Smith, Peter G. (31 March 2020). "Human challenge studies to accelerate coronavirus vaccine licensure". The Journal of Infectious Diseases 221 (11): 1752–1756. doi:10.1093/infdis/jiaa152. PMID 32232474. PMC 7184325. https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa152/5814216. Retrieved 19 April 2020. 
  140. "Should scientists infect healthy people with the coronavirus to test vaccines?". Nature 580 (7801): 17. April 2020. doi:10.1038/d41586-020-00927-3. PMID 32218549. https://www.nature.com/articles/d41586-020-00927-3. Retrieved 19 April 2020. 
  141. Eric Boodman (13 March 2020). "Coronavirus vaccine clinical trial starting without usual animal data". STAT. https://www.statnews.com/2020/03/11/researchers-rush-to-start-moderna-coronavirus-vaccine-trial-without-usual-animal-testing/. 
  142. Cohen, Jon (31 March 2020). "Speed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn". Science. doi:10.1126/science.abc0006. https://www.sciencemag.org/news/2020/03/speed-coronavirus-vaccine-testing-deliberately-infecting-volunteers-not-so-fast-some. Retrieved 19 April 2020. 
  143. Walker, P.; Whittaker, C.; Watson, O.; Baguelin, M.; Ainslie, K.; Bhatia, S.; Bhatt, S.; Boonyasiri, A. et al. (26 March 2020). The global impact of COVID-19 and strategies for mitigation and suppression. Imperial College COVID-19 Response Team. doi:10.25561/77735. https://spiral.imperial.ac.uk:8443/bitstream/10044/1/77735/10/2020-03-26-COVID19-Report-12.pdf. Retrieved 19 April 2020. 
  144. "Key criteria for the ethical acceptability of COVID-19 human challenge studies". World Health Organization. 2020-05-06. https://apps.who.int/iris/bitstream/handle/10665/331976/WHO-2019-nCoV-Ethics_criteria-2020.1-eng.pdf. 
  145. Weintraub, Rebecca; Yadav, Prashant; Berkley, Seth (2020-04-02). "A COVID-19 vaccine will need equitable, global distribution". Harvard Business Review. ISSN 0017-8012. https://hbr.org/2020/04/a-covid-19-vaccine-will-need-equitable-global-distribution. 
  146. "COVID-19 pandemic reveals the risks of relying on private sector for life-saving vaccines, says expert". CBC Radio. 2020-05-08. https://www.cbc.ca/radio/thesundayedition/the-sunday-edition-for-may-10-2020-1.5554451/covid-19-pandemic-reveals-the-risks-of-relying-on-private-sector-for-life-saving-vaccines-says-expert-1.5554463. 
  147. Ahmed, Darius D. (2020-06-04). "Oxford, AstraZeneca COVID-19 deal reinforces 'vaccine sovereignty'". STAT. https://www.statnews.com/2020/06/04/oxford-astrazeneca-covid-19-deal-reinforces-vaccine-sovereignty/. 
  148. Blankenship, Kyle (2020-06-04). "AstraZeneca unveils massive $750M deal in effort to produce billions of COVID-19 shots". FiercePharma. https://www.fiercepharma.com/manufacturing/astrazeneca-unveils-massive-750m-deal-effort-to-produce-billions-covid-19-shots. 
  149. Cohen, Jon (2020-06-04). "Top U.S. scientists left out of White House selection of COVID-19 vaccine short list". Science. doi:10.1126/science.abd1719. ISSN 0036-8075. https://www.sciencemag.org/news/2020/06/top-us-scientists-left-out-white-house-selection-covid-19-vaccine-shortlist. Retrieved 10 June 2020. 
  150. Bollyky, Thomas J.; Gostin, Lawrence O.; Hamburg, Margaret A. (2020-05-07). "The equitable distribution of COVID-19 therapeutics and vaccines". JAMA. doi:10.1001/jama.2020.6641. https://jamanetwork.com/journals/jama/fullarticle/2765944. Retrieved 10 June 2020. 
  151. Aakash, B; Faulconbridge, Guy; Holton, Kate (2020-05-22). "U.S. secures 300 million doses of potential AstraZeneca COVID-19 vaccine". The Guardian. Reuters. https://www.theguardian.pe.ca/news/world/astrazeneca-gets-first-supply-agreements-for-covid-19-vaccine-452225/. 
  152. Paton, James; Griffin, Riley; Koons, Cynthia. "U.S. likely to get Sanofi vaccine first if it succeeds". Bloomberg. https://www.bloombergquint.com/business/u-s-to-get-sanofi-covid-vaccine-first-if-it-succeeds-ceo-says. 
  153. "Serum Institute investing US$100 million on potential COVID-19 vaccine". The Economic Times. 2020-06-09. https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/serum-institute-investing-usd-100-million-on-potential-covid-19-vaccine/articleshow/76288408.cms. 
  154. Roy, Abhirup; Rocha, Euan (2020-05-22). "How one Indian company could be world's door to a COVID-19 vaccine" (in en). Reuters. https://www.reuters.com/article/us-health-coronavirus-india-serum-insigh-idUSKBN22Y2BI. 
  155. Khamsi, Roxanne (2020-04-09). "If a coronavirus vaccine arrives, can the world make enough?" (in en). Nature 580: 578–580. doi:10.1038/d41586-020-01063-8. https://www.nature.com/articles/d41586-020-01063-8. Retrieved 10 June 2020. 
  156. Gretler, Corinne (2020-05-18). "China pledges to make its coronavirus vaccine a 'public good'". The National Post (Bloomberg). https://nationalpost.com/news/world/china-pledges-to-make-its-coronavirus-vaccine-a-public-good. 
  157. "CEPI welcomes UK Government's funding and highlights need for $2 billion to develop a vaccine against COVID-19". Coalition for Epidemic Preparedness Innovations, Oslo, Norway. 6 March 2020. https://cepi.net/news_cepi/2-billion-required-to-develop-a-vaccine-against-the-covid-19-virus/. 
  158. Huneycutt, Brenda; Lurie, Nicole; Rotenberg, Sara; Wilder, Richard; Hatchett, Richard (2020-02-24). "Finding equipoise: CEPI revises its equitable access policy". Vaccine 38 (9): 2144–2148. doi:10.1016/j.vaccine.2019.12.055. PMID 32005536. PMC 7130943. https://linkinghub.elsevier.com/retrieve/pii/S0264410X19317190. Retrieved 10 June 2020. 
  159. "Vaccine for COVID-19". The Center for Artistic Activism. 2020-03-22. https://c4aa.org/2020/03/join-us-free-the-vaccine-for-covid-19. 
  160. "UAEM response to COVID-19". Universities Allied for Essential Medicines. 2020. https://uaem.org/. 
  161. Azar, Alex (4 February 2020). "Notice of Declaration under the Public Readiness and Emergency Preparedness Act for medical countermeasures against COVID-19". https://www.phe.gov/Preparedness/legal/prepact/Pages/COVID19.aspx. 
  162. Kertscher, Tom (23 January 2020). "No, there is no vaccine for the Wuhan coronavirus". Poynter Institute. https://www.politifact.com/factchecks/2020/jan/23/facebook-posts/there-outbreak-china-wuhan-coronavirus-there-not-v/. 
  163. McDonald, Jessica (24 January 2020). "Social Media Posts Spread Bogus Coronavirus Conspiracy Theory". Annenberg Public Policy Center. https://www.factcheck.org/2020/01/social-media-posts-spread-bogus-coronavirus-conspiracy-theory/. 
  164. "WARNING LETTER – North Coast Biologics – MARCS-CMS 607532". U.S. Food and Drug Administration (FDA). 21 May 2020. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/north-coast-biologics-607532-05212020. 
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Medicine, Research & Experimental
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
HandWiki
View Times: 3.1K
Entry Collection: HandWiki
Revision: 1 time (View History)
Update Date: 09 Nov 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback